# BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

> **NCT02763384** · PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 12 (actual)

## Conditions studied

- T-Acute Lymphoblastic Leukemia
- Adult T Lymphoblastic Lymphoma

## Interventions

- **DRUG:** BL-8040
- **DRUG:** Nelarabine

## Key facts

- **NCT ID:** NCT02763384
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-02
- **Primary completion:** 2022-02-11
- **Final completion:** 2022-05-22
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2023-10-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02763384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02763384, "BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02763384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*